Investors Capital Advisory Services’s Alexion Pharmaceuticals ALXN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q2
$233K Buy
1,996
+14
+0.7% +$1.99K 0.04% 526
2016
Q1
$275K Buy
1,982
+131
+7% +$19.2K 0.05% 446
2015
Q4
$353K Sell
1,851
-729
-28% -$127K 0.07% 395
2015
Q3
$403K Hold
2,580
0.08% 346
2015
Q2
$466K Buy
2,580
+525
+26% +$90.6K 0.09% 337
2015
Q1
$356K Buy
2,055
+250
+14% +$45.3K 0.07% 404
2014
Q4
$333K Buy
1,805
+128
+8% +$23.7K 0.06% 406
2014
Q3
$278K Buy
+1,677
New +$275K 0.05% 458

Other funds holding ALXN

Investors Capital Advisory Services's ALXN Position: Q2 2016 in Review

Investors Capital Advisory Services increased its Alexion Pharmaceuticals (ALXN) stake by 0.71% in Q2 2016, buying an estimated $1.99K and bringing the position to 1,996 shares worth $233K. The position accounts for 0.04% of the portfolio, ranked #526.

Investors Capital Advisory Services first reported a position in ALXN in Q3 2014 and has held it in 8 quarters since. The position peaked at $466K in Q2 2015. 534 funds tracked by Wall St. Rank hold ALXN as of Q2 2016.

  • Investors Capital Advisory Services held 1,996 shares of Alexion Pharmaceuticals worth $233K as of Q2 2016.
  • Investors Capital Advisory Services bought 14 Alexion Pharmaceuticals shares in Q2 2016, an estimated $1.99K.
  • Alexion Pharmaceuticals made up 0.04% of Investors Capital Advisory Services's portfolio in Q2 2016, its #526 holding.
  • Investors Capital Advisory Services first reported a position in Alexion Pharmaceuticals in Q3 2014 and has held it in 8 quarters since.
  • Investors Capital Advisory Services's Alexion Pharmaceuticals position peaked at $466K in Q2 2015.
  • 534 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2016.

Based on Investors Capital Advisory Services's 13F filing for Q2 2016, filed 2 Aug 2016.